India's Alivus rises to 15-month high as brokerages optimistic about drugmaker's annual outlook

Alivus Life Sciences

03/08/2026 08:20

** Shares of Indian drugmaker Alivus Life Sciences ALIV.NS rise 4.4% to 1,210.60 rupees, their highest level since May 2025
** Stock set for second consecutive session of gains, if trend holds
** Company upgrades its sales growth outlook after first-quarter results to 10%-12% y/y for FY27, from single-digit pct growth earlier
** Kotak Institutional Equities ("buy") raises TP to 1,400 rupees from 1,315 rupees 
** Brokerage says company's EBITDA margin guidance of 30%-32% in FY27 is conservative
** Brokerage expects margin expansion from new launches, benefits from new capacity ramp-up to drive growth
** Investec ("buy") raises TP to 1,375 rupees from 1,240 rupees, expects strong growth momentum especially in H2FY27
** ALIV rated "buy" on avg by four analysts; median PT is 1,352.50 rupees - LSEG-compiled data
** Stock up 32.1%, YTD 
     

 (Reporting by Abhirami G in Bengaluru)
 ((abhirami.g@thomsonreuters.com))